



Molecular Detection of blaTEM, blaCTX-M and blaSHV Genes in Extended Spectrum β -Lactamase (ESBL) *Escherichia coli* from Clinical Samples

Mahesh Kumar Chaudhary ^{a,b*}, Indrani Jadhav ^c and Megha Raj Banjara ^d

^a School of Life and Basic Sciences, Jaipur National University, Jaipur, India.

^b Department of Microbiology, Nepal Medciti Hospital, Lalitpur, Nepal.

^c School of Life and Basic Sciences, Jaipur National University, Jaipur, India.

^d Department of Microbiology, Tribhuvan University, Kirtipur, Nepal.

Authors' contributions

This work was carried out in collaboration among all authors. Authors MKC and IJ managed the analysis and interpretation of data, drafting article, final approval to be submitted. Author MRB drafted the article, final approval to be submitted. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMMR/2022/v34i234864

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/93917>

Original Research Article

Received 12 September 2022

Accepted 17 November 2022

Published 24 November 2022

ABSTRACT

Introduction: Extended spectrum β -lactamases are the group of β -lactamase enzymes which confer resistance to the oxyimino-cephalosporins and monobactams.

Study Design: Cross-sectional prospective study.

Place and Duration of Study: This study was conducted over a period of 2 years (September 2018 to April 2020) at microbiology laboratory of Nepal Medciti Hospital.

Methodology: Clinical samples were processed in microbiology laboratory and culture isolates were characterized by standard microbiological techniques following standard procedures. Antibiotic susceptibility testing was performed by modified Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute. Extended spectrum β lactamases were phenotypically confirmed by combined disc method. ESBL producing genes i.e. blaTEM, blaCTX-M and blaSHV were confirmed by PCR.

Results: Of the 1449 total *Escherichia coli* isolates, 323/1449(22.29%) isolates were multidrug resistance. Among total MDR *E. coli* isolates, 215/323(66.56%) isolates were ESBL producers. The maximum number of ESBL *E. coli* was isolated from urine 194(90.23%), followed by sputum

12(5.58%), swab 5 (2.32%), pus 2 (0.93%) and blood 2 (0.93%). Antibiotic susceptibility pattern of ESBL *E. coli* producers showed highest sensitivity towards tigecycline (100%) followed by polymyxin B, colistin and meropenem. Out of 215 phenotypically confirmed ESBL *E. coli*, only 186(86.51%) isolates were found to positive by PCR. The last 29(13.49%) were negative for any of the resistant genes. Among the ESBL genotypes, most common was blaTEM 118(63.4%) followed by blaCTX-M 68(36.6%).

Conclusion: The emergence of ESBL producing *E. coli* isolates with high antibiotic resistant rates to commonly used antibiotics and increased predominance of major gene types blaTEM is a serious concern to the clinicians as well as microbiologist. This study forwarded a real message to all the clinicians for the emergence of XDR and PDR resistant bacteria and preservation of antibiotics for their proper use in near future, if past experience with MDR and ESBLs is any indicator.

Aims: This study was focused to find out the ESBL producing *Escherichia coli* and detection of TEM, SHV and CTXM genes by Polymerase Chain Reaction (PCR).

Keywords: *E. coli*; extended spectrum β -lactamase; multidrug resistant.

ABBREVIATIONS

ESBL : Extended Spectrum β - Lactamase
 MDR : Multi Drug Resistant
 bla : β -lactamase coding gene
 ATCC : American Type Culture Collection
 CLSI : Clinical Laboratory Standard Institute
 CTX-M : Cefotaximase, Munich
 TEM : Temoniera gene
 SHV : Sulphydril variable

1. INTRODUCTION

Extended spectrum β - lactamases (ESBLs) are plasmid mediated enzymes which belong to the group of β -lactamase enzymes, which are able to hydrolyze and develop resistance to 3rd generation cephalosporins (cefotaxime, ceftazidime, ceftriaxone, cefuroxime and cefepime) and monobactams (aztreonam), without affecting cephamycins (cefotetan) or carbapenems (imipenem, meropenem, and ertapenem) [1,2].

The first ESBL was detected from Germany in 1983 and in 1985 from France and at the end of 1980s, and the beginning of the 1990s from United States [3]. The emergence of New TEM and SHV enzymes are still existing in Europe, and found to have distinct epidemic clones, for example SHV-12 detected in *Escherichia coli* and *Klebsiella pneumoniae* isolates in Italy [4]. CTX-M-9 group are commonly found in isolates in Spain and CTX-M-3 enzymes have been identified the major strains in Eastern Europe, although variants of CTX-M group 1 (including the CTX-M-15 type) are the most widespread throughout Europe [3,4].

The rapid increase in extended spectrum β -lactamases with the existence of multidrug resistant organisms is a global problem. The prevalence of ESBL producing organisms is more than 20% in Asia and South Africa. The detection of major genes such as blaTEM, blaCTX-M and blaSHV in ESBL producing *E. coli* by molecular methods and their antibiotic resistance pattern can provide valuable information about their epidemiology and help in formulation of rational antimicrobial therapy [5].

In Developing country like Nepal also due to the increasing incidence of ESBL producing *Escherichia coli*, the cost associated with the consequences also rises, so considers as an economic burden on the patients both in community and in hospital. Therefore, this study was conducted with the objectives of studying the spectrum of MDR and ESBL *Escherichia coli* producing strains and detection of TEM, SHV and CTX-M genes by Polymerase Chain Reaction. Characterization of ESBL *Escherichia coli* at molecular level may be beneficial to analyze the root cause of ESBL pattern which may help to make a positive contribution to current understanding and knowledge of the situation caused by ESBL *Escherichia coli* producing strains and for the development of better treatment strategy and prevention of the disease.

2. MATERIALS AND METHODS

2.1 Sample Processing and Identification of Organisms

A cross sectional prospective study was conducted in Microbiology Laboratory of Nepal

Mediciti Hospital, Bhaisepati; Nepal from September 2018 to April 2020. A total of 16542 clinical samples sent to the microbiology laboratory were processed and cultured by standard microbiological techniques. The identification of bacterial isolates were carried out by cultural, morphological characters, Gram stain and appropriate biochemical tests (triple sugar iron, indole, citrate, urease and motility) following standard procedures.

2.2 Antibiotic Susceptibility Tests

Antibiotic susceptibility testing was performed by modified Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute [6]. The antibiotics used were amikacin (30µg), gentamycin (10µg), ciprofloxacin (30µg), ceftriaxone (30µg), cefotaxime (30µg), ceftazidime (30µg), nitrofurantoin (300µg), norfloxacin (10µg), nalidixic acid (30µg) ofloxacin (5µg), cotrimoxazole (25µg), cefixime (5µg), cefepime (30µg), tigecycline (15µg), imipenem (10µg), meropenem (10µg), polymyxin B (300µg) and colistin (10µg). Plates were incubated aerobically at 37°C for 24 hours. Zone diameter in millimeters was measured and organisms were identified as sensitive, resistant and intermediate as per CLSI 2017 guidelines. *Escherichia coli* strain ATCC 25922 was used as control strain.

2.3 Screening of ESBL

The screening was done by disc diffusion technique using 3rd generation cephalosporins (ceftazidime, cefotaxime and ceftriaxone). Isolates resistant to more than one of these agents were identified as possible ESBL producers [7].

2.4 Confirmation of ESBL

For confirmation, combined disc test was performed using Ceftazidime (30µg) alone and ceftazidime with clavulanic acid (30µg/10µg) and cefotaxime (30µg) and cefotaxime with clavulanic acid (30µg/10µg). A difference in zone of inhibition by ≥5mm of either of ceftazidime clavulanic acid with ceftazidime alone and cefotaxime clavulanic acid with cefotaxime alone was interpreted as confirmed ESBL [7].

2.5 Gene Identification

From confirmed ESBL *E. coli*, plasmid DNA was extracted using alkaline hydrolysis method.

These plasmid DNA served as a template for PCR amplification using blaTEM, blaCTX-M and blaSHV specific primers (Maregen, Korea). For PCR amplification, 1.5µl plasmid DNA was added to 25 µl mixture containing 13 µl master mixture (Solis Biodyne, Estonia), 10.5µl nuclease free water and 0.5µl each of reverse and forward primers. PCR was performed in 5 Prime/02 thermal cycler using optimized condition. Bibby Scientific, U.K. using optimized condition. For blaTEM gene identification, initial denaturation at 94°C for 5 minutes followed by 30 cycles of each of denaturation (95°C for 45 seconds), annealing at (50°C for 45 seconds), and extension at (72°C for 30 seconds), and final extension at (72°C for 10 minutes). For blaSHV and blaCTX-M genes, initial denaturation at 94°C for 5 minutes followed by 30 cycles of each of denaturation (95°C for 45 seconds), annealing at 56°C for 45 seconds and 62°C for 45 seconds respectively, and extension at (72°C for 30 seconds), and final extension at (72°C for 10 minutes). The amplified product was subjected to gel electrophoresis (2% gel stained with ethidium bromide) at 70v for 45 minutes. DNA ladder (100bp) was used to estimate the molecular weight of amplified products. After electrophoresis, gel doc system was used for photo documentation.

2.6 Control

For ESBL test, *Escherichia coli* (ATCC 25922), *Klebsiella pneumoniae* (ATCC 700603) were taken as negative control and positive control respectively. Confirmed *Escherichia coli* strains harbouring blaTEM, blaSHV, blaCTX-M were taken as positive control and nuclease free water as negative control.

2.7 Statistical Analysis

Data were entered and percentage were calculated and analyzed by using Statistical Package for Social Science (SPSS) version 21.

3. RESULTS

1449 *E. coli* isolates were recovered from various clinical samples. The highest number of *E. coli* was isolated from urine followed by sputum, swab, pus, blood, fluid, foley's tip, vaginal swab, catheter tip, BAL, biopsy, bile suction tube, CVP tip, ET tube. Of the 1449 total *E. coli* isolates, 323/1449(22.29%) isolates were multidrug resistance. Among total MDR *E. coli* isolates, 215/323(66.56%) isolates were ESBL producers.

The maximum number of ESBL *Escherichia coli* was isolated from urine 194(90.23%), followed by sputum 12(5.58%), swab 5 (2.32%), pus 2 (0.93%) and blood 2 (0.93%) (Table 1).

Antibiotic susceptibility pattern of ESBL *E. coli* producers showed highest sensitivity towards tigecycline (100%) followed by polymyxin b, colistin and meropenem (Table 2).

Table 1. Distribution of ESBL *E. coli* from clinical samples

Specimen	ESBL <i>E. coli</i> No (%)
Urine	194(90.23%)
Sputum	12(5.58%)
Swab	5(2.32%)
Pus	2(0.93%)
Blood	2(0.93%)
Total	215(100.0)

Two hundred fifteen ESBL *E. coli* isolates were confirmed by PCR using *bla*TEM, *bla*CTX-M and *bla*SHV specific primers. Out of 215 phenotypically confirmed ESBL *E. coli*, only 186(86.51%) isolates were found to positive by PCR (Table 3).

The last 29(13.49%) were negative for any of the resistant genes. Among the ESBL genotypes, most common was *bla*TEM 118(63.4%) followed by *bla*CTX-M 68(36.6%). The co-existence of *bla*TEM and *bla*CTX-M in ESBL producing *E. coli* was 39(20.96%). No ESBL *E. coli* isolates co-harbored *bla*SHV and *bla*TEM, *bla*CTX-M and *bla*SHV or all three genes at the same time.

4. DISCUSSION

Despite the discovery of antibiotics, emergence of MDR and ESBLs producing bacteria due to the extensive use of extended spectrum cephalosporins (ESCs) since early 1980's is a significant evolution in antimicrobial resistance. Several other factors including misuse of drugs, inappropriate antibiotic treatment, extensive use of antimicrobials also contributed to the emergence of drug resistant bacteria. The present study was conducted in the department of microbiology laboratory, Nepal Mediciti Hospital during a period of September 2018 to April 2020 with the aim of understanding the antibiotic profile of MDR and ESBL producing *Escherichia coli*.

In this study, a significantly high number of *E. coli* isolates were recovered from urine (75.77 %). With respect to urinary tract infection, *E. coli* showed a significant resistance towards nalidixic acid, co-trimoxaloz, and 3rd generation cephalosporins. This co-relates with other study done in other parts of Nepal [8,9]. However, 73% resistant to ceftriaxone were reported in *E. coli* isolates by Fanta et al. [10]. The reason for third generation cephalosporins resistance may be due to the extensive use of drugs [11].

In Urinary Tract Infection, highest sensitivity was found to nitrofurantoin (96.5%) followed by amikacin (80.7%) and gentamycin (73.9%). Various studies have been reported similar findings [12-14]. This may be due to the proper use of these drugs in UTIs cases since these are the first line drugs for UTIs.

Table 2. Antibiotic susceptibility pattern of ESBL *E. coli*

Antibiotics	Antibiotic susceptibility rate No (%) ESBL <i>E. coli</i> (215)	
	Sensitive	Resistant
Amikacin(AK)	197(91.6)	18(8.4)
Gentamycin(G)	180(83.7)	35(16.3)
Ciprofloxacin(CIP)	125(58.2)	90(41.8)
Ceftriaxone(CTR)	0(0.0)	215(100)
Cefotaxime(CTX)	1	214(97.3)
Ceftazidime(CAZ)	0(0.0)	215(100)
Nitrofurantoin(NIT)*	182(93.8)	12(6.2)
Norfloxacin(NX)*	109(56.2)	85(43.8)
Nalidixic acid(NA)*	9(4.6)	185(95.4)
Ofloxacin(OF)*	91(46.9)	103(53.1)
Tigecycline(TGC)	215(100)	0(0.0)
Imipenem(IPM)	148(68.8)	67(31.2)
Meropenem(MRP)	194(90.2)	21(9.8)
Polymyxin B(PB)	210 (97.67)	5 (2.33)
Colistin(CL)	211 (98.13)	4 (1.86)

*Used in urine culture

The analysis of antibiotic susceptibility of *E. coli* isolated from sputum, blood, swab, pus demonstrated a significant degree of sensitivity towards tigecycline (100%) followed by colistin (98% to 100%), polymyxin B (97% to 100%), meropenem (91% to 96%) and imipenem (79% to 90%). Similar results were shown in other studies [15,16]. It was found to be higher resistant pattern of cephalosporins (22% to 93%), fluoroquinolones (26% to 85%), aminoglycosides (8% to 59%) as compared to urine isolates. Several studies conducted in Nepal showed similar results [13,17]. In contrast to this study, a slightly higher sensitivity was detected towards cephalosporins, fluoroquinolones, aminoglycosides by Bamford et al. [18]. The increasing trends of drugs resistance towards internationally recommended first line drugs is a major concern worldwide [19]. and are irrational used in public and private sectors [20].

Table 3. Distribution of ESBL genotypes in *E. coli*

ESBL genotypes	ESBL producing <i>E. coli</i> (n=186) No (%)
blaTEM	118(63.4%)
blaCTX-M	68(36.6%)
blaTEM + blaCTX-M	39(20.96%)
blaSHV	0(0)

The prevalence of ESBL *E. coli* was (215/323) 66.56% which was alarming high. Several studies reported high prevalence i.e.40-70% of ESBL *E. coli* among MDR *E. coli*. [9,14,16,21, 22]. But the study conducted by Onyedibe, K et al. [23]. in 2018 observed only 18.6% ESBL prevalence in *E. coli* which is analogous to other study [24]. This is not similar with our study due to variation in geography, study design and selection of type of antimicrobial agents. The indiscriminate use of β lactam antibiotics leads to generation of selective pressures which have led to the selection of a variety of mutated forms of β lactamases. [25].

The analysis of antibiotic susceptibility profile of ESBL *E. coli* isolates documented higher sensitivity rates to tigecycline (100%), polymyxin B (100%), colistin (100%) followed by amikacin (91.6%), meropenem (90.2%) and imipenem (68.8%). Sensitivity to nitrofurantoin was 93.8% against ESBL producing *E. coli* isolates from urine. So, it is the drug of choice for treating infection caused by ESBL producing *E. coli*.

The result of similar study conducted in India [26,27].

In this study, the overall prevalence of ESBL genes was 186 (86.51%).Which is similar to other findings reported by Dirar et al. [28]. in Sudan, Ahmad et al. [29]. in Iraq. PCR analysis revealed the presence of blaTEM, blaCTX-M and blaSHV genes in ESBL producing *E. coli* was 118 (63.4%), 68 (36.6%) and 0 (0) respectively.

In the present study, blaTEM was the most predominant genotype of ESBL among *E. coli* isolates. This study is well supported by Dirar et al. [28] in Sudan, Ahmad et al. [29] in Iraq, Noha et al. [30] in Upper Egypt, Majid et al. [31] in Iran, Pandit et al. [32] in Nepal, Michael et al., 2018 [33] in Iraq, Sahoo et al. [34] in India, Jena et al. [35] in India.

The presence of multiple genotypes in a single isolate might be the result of complex antibiotic resistance pattern. Our findings does not agree with the study of Kpoda et al. [36] and Sadeghi et al. [37] where they reported blaTEM and blaSHV type (24.6%) and (34.7%) respectively. Similarly, Lohani et al. [38] reported CTX-M +TEM and CTX-M +SHV type (21.2%) and (19.2%) respectively.

Regarding the blaSHV gene, no blaSHV type *E. coli* was detected in our study. This is similar to study done in Nigeria [39]. However, several findings in Nepal reported the prevalence of blaSHV gene [38,40].

5. CONCLUSION

In conclusion, the present study highlights the emergence of MDR and ESBL producing *E. coli* isolates with high antibiotic resistant rates to commonly used antibiotics and increased predominance of major gene types blaTEM is a serious concern to the clinicians as well as microbiologist. Since the spread of MDR and ESBL producing *E. coli* has been increasing rapidly worldwide including developing country like Nepal, treatment options for resistant bacteria have been increasingly sorted. In the present study, no resistance was documented to tigecycline, polymyxin B, and colistin suggesting the suitable drug of choice for treating ESBL producing *E. coli* causing life threatening infections. Therefore, molecular detection and identification of ESBL producing bacterial isolates should be essential at routine laboratory

level. Of particular concern, our findings emphasizes the need for implementation of strict antibiotic policy, clinical care management and antibiotic stewardship program absolutely required in each and every health sectors to minimize the increasing trends of MDR and ESBL isolates by all concern authorities which will help in reduction of mortality of patients. This study forwards a real massage to all clinicians for the emergence of XDR and PDR resistant bacteria and preservation of antibiotics for their proper use in near future, if past experience with MDR and ESBLs is any indicator.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The ethical approval was taken from the Ethical Review Board of Nepal Health Research Council (NHRC), Kathmandu, Nepal.

DISCLAIMER

This paper is an extended version of a preprint document of the same author.

The preprint document is available in this link: <https://assets.researchsquare.com/files/rs-965153/v1/5b8223d1-e0d2-40ab-9615-9065aeb00189.pdf?c=1637577232>.

ACKNOWLEDGEMENT

We would like to acknowledge Nepal Medicit Hospital, Nepal for providing ethical approval and research work. We also thank to the microbiology laboratory staffs for their valuable support to complete this work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: definition, classification and epidemiology. *Curr. Issues Mol. Biol.* 2015;17(1):11-22. DOI:<https://doi.org/10.21775/cimb.017.011>
2. Ghenea AE, Zlatian OM, Cristea OM, Ungureanu A, Mititelu RR, Balasoiu AT, Vasile CM, Salan AI, Iliuta D, Popescu M, Udriștoiu AL, Balasoiu M. TEM, CTX-M, SHV Genes in ESBL-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolated from Clinical Samples in a County Clinical Emergency Hospital Romania-Predominance of CTX-M-15. *Antibiotics (Basel)*. 2022 Apr 10;11(4):503. DOI:<https://doi.org/10.3390%2Fantibiotics11040503>
3. Shaikh S, Fatima J, Shakil S, Mohd S, Rizvi D, Mohammad AK. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment, *Saudi Journal of Biological Sciences*. 2015;22(1):90-101. ISSN 1319-562X, DOI:<https://doi.org/10.1016/j.sjbs.2014.08.002>
4. Perilli M, Segatore B, Mugnaioli C, Celenza G, Rossolini GM, Stefani S, Luzzaro F, Pini B, Amicosante G. Persistence of TEM-52/TEM-92 and SHV-12 extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Italy. *Microb. Drug Resist.* 2011;17 (4), 521–524. DOI:<https://doi.org/10.1089/mdr.2011.0059>
5. Kaur M, Aggarwal A. Occurrence of the CTX-M, SHV and the TEM genes among the extended spectrum beta-lactamase producing isolates of enterobacteriaceae in a Tertiary Care Hospital of North India. *Journal of Clinical and Diagnostic Research*. 2013;7:642-645. DOI:<https://doi.org/10.7860/JCDR/2013/5081.2872>
6. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplements M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
7. CLSI Performance Standards for Antimicrobial Susceptibility Testing; 30th ed. CLSI supplements. M100. Wayne, PA: Clinical and Laboratory Standard Institute; 2020.
8. Guragain N, Pradhan A, Dhungel B, Banjara MR, Rijal KR, Ghimire P. Extended spectrum beta-lactamase producing gram negative bacterial isolates from urine of patients visiting Everest Hospital, Kathmandu, Nepal. *Tribhuvan University Journal of Microbiology*. 2019;6, 26–31.

- DOI:<https://doi.org/10.3126/tujm.v6i0.26575>
9. Khanal LK, Amatya R, Sah AK, Adhikari RP, Khadka S, Sapkota J, Rai SK. Prevalence of extended spectrum beta lactamase producing *Escherichia coli* and *Klebsiella* spp. from urinary specimen in a tertiary care hospital. Nepal Medical College Journal. 2022;24(1):75–80. DOI:<https://doi.org/10.3126/nmcj.v24i1.44145>
 10. Fanta G, Eshetu M, Mekidim M, Gemechu Z. Antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins. Journal of Pharmaceutics. 2018;7ID5070742qeikwfejkdf DOI:<https://doi.org/10.1155/2018/5070742>
 11. Mitman SL, Amato HK, Saraiva-Garcia C, Loayza F, Salinas L, Kurowski K, et al. Risk factors for third-generation cephalosporin-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* carriage in domestic animals of semirural parishes east of Quito, Ecuador. PLOS Glob Public Health. 2022;2(3): e0000206. DOI:<https://doi.org/10.1371/journal.pgph.0000206>
 12. Salem MA, Ahmed FA. Bacterial profile of urinary tract infection and antimicrobial susceptibility pattern among patients attending at bushra medical laboratory, Tripoli, Libya. Journal of Gastroenterology and Hepatology Research. 2018;7(4): 2671-2675. Available:<http://www.ghrnet.org/index.php/joghr/article/view/2380>
 13. Subedi S, Chaudhary M, Shrestha B. High MDR AND ESBL Producing *Escherichia coli* and *Klebsiella pneumoniae* from Urine, Pus and Sputum Samples. British Journal of Medicine & Medical Research. 2016;13(10):1-10. DOI:<http://dx.doi.org/10.9734/BJMMR/2016/23350>
 14. Rimal U, Thapa S, Maharjan R. Prevalence of extended spectrum beta-lactamase producing *Escherichia coli* and *Klebsiella* species from urinary specimens of children attending Friendship International Children's Hospital. Nepal Journal of Biotechnology. 2017;5(1):32-38. DOI:<http://dx.doi.org/10.3126/njb.v5i1.18868>
 15. Naqid IA, Balatay AA, Hussein NR, Saeed KA, Ahmed HA, et al. Antibiotic susceptibility pattern of *Escherichia coli* isolated from various clinical samples in Duhok City, Kurdistan Region of Iraq. Int J Infect. 2020;7(3):e103740. DOI:<https://dx.doi.org/10.5812/iji.103740>
 16. Shilpakar A, Ansari M, Rai KR, Rai G, Rai SK. Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal. Trop Med Health. 2021 Mar 11;49(1):23. DOI:<https://doi.org/10.1186/s12941-021-00313-3>
 17. Yadav K, Prakash S. Screening of ESBL producing multidrug resistant *E. coli* from urinary tract infection suspected cases in southern terai of Nepal. J Infect Dis Diagn. 2017;2:2 DOI:<https://dx.doi.org/10.4172/2576-389x.1000116>
 18. Kubone PZ, Mlisana KP, Govinden U, Abia ALK, Essack SY. Antibiotic susceptibility and molecular characterization of uropathogenic *Escherichia coli* associated with community-acquired urinary tract infections in urban and rural settings in South Africa. Tropical Medicine and Infectious Disease. 2020;5(4):176. DOI:<https://doi.org/10.3390/tropicalmed5040176>
 19. Iftekhar A, Md. Bodiuzzaman R, Sakina S. Antibiotic resistance in Bangladesh: A systematic review. International Journal of Infectious Diseases. 2019;80(54-61). DOI:<https://doi.org/10.1016/j.ijid.2018.12.017>
 20. Rijal KR, Banjara MR, Dhungel B, et al. Use of antimicrobials and antimicrobial resistance in Nepal: a nationwide survey. Sci Rep. 2021;11:11554. DOI:<https://doi.org/10.1038/s41598-021-90812-4>
 21. Manandhar S, Zellweger RM, Maharjan N, et al. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes. Ann Clin Microbiol Antimicrob. 2020;19:48. DOI:<https://doi.org/10.1186/s12941-020-00390-y>
 22. Sadeghi M, Sedigh Ebrahim-Saraie H, Mojtahedi A. Prevalence of ESBL and AmpC genes in *E. coli* isolates from urinary

- tract infections in the north of Iran. *New Microbes New Infect.* 2021 Nov 20; 45:100947.
DOI:https://doi.org/10.1016%2Fj.nmni.2021.100947
23. Onyedibe K, Shobowale E, Okolo M, Iroezindu M, Afolaranmi T, Nwaokorie F, Opajobi S, Isa S, Egah D. Low prevalence of carbapenem resistance in clinical isolates of extended spectrum beta lactamase (ESBL) producing *Escherichia coli* in North Central, Nigeria. *Advances in Infectious Diseases.* 2018;8:109-120.
DOI:https://doi.org/10.4236/aid.2018.83011
 24. Vachvanichsanong P, McNeil E, Dissaneewate P. Extended-spectrum beta-lactamase *Escherichia coli* and *Klebsiella pneumoniae* urinary tract infections. *Epidemiology and Infection.* 2021;149:E12.
DOI:https://doi.org/10.1017/S095026882003015
 25. Chanu TR, Shah PK, Soni S, Ghosh A. Phenotypic detection of extended spectrum, AmpC, Metallo beta-lactamases and their coexistence in clinical isolates of commonly isolated gram negative bacteria in GKGH hospital, Bhuj. *IP Int J Med Microbiol Trop Dis.* 2019;5(1):52-56.
DOI:https://doi.org/10.18231/2581-4761.2019.0012
 26. Gharavi MJ, Zarei J, Roshani-Asl P, Yazdanyar Z, Sharif M, Rashidi N. Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. *Sci Rep.* 2021 Jan 12;11(1):578.
DOI:https://doi.org/10.1038%2Fs41598-020-79791-0
 27. Sharmal Kumar M, Arunagirinathan N, Ravikumar M. Antibiotic susceptibility profile of extended spectrum β -lactamase producing *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca* from Urinary tract infections. *Research Journal of Pharmacy and Technology.* 2021;14(8): 4425-8.
DOI:https://doi.org/10.52711/0974-360X.2021.00768
 28. Dirar MH, Bilal NE, Ibrahim ME, Hamid ME. Prevalence of extended-spectrum β -lactamase (ESBL) and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Enterobacteriaceae isolates from patients in Khartoum, Sudan. *Pan Afr Med J.* 2020 Nov 3;37:213.
DOI:https://doi.org/10.11604%2Fpamj.2020.37.213.24988
 29. Ahmad Hamad P, Khadija KM. Prevalence of blaTEM, blaSHV, and blaCTX-M genes among ESBL-producing *Klebsiella pneumoniae* and *Escherichia coli* isolated from thalassemia in Erbil, Iraq. *Mediterranean Journal of Hematology and Infectious Diseases.* 2019;11(1):e2019041.
DOI:https://doi.org/10.4084/mjihid.2019.041
 30. Noha AH, Ahmed SK, Eman MF, Adel MH, Medhat AF. Molecular characterization of Extended-spectrum β lactamase-producing *E. coli* recovered from community-acquired urinary tract infections in Upper Egypt. *Sci Rep.* 2020;10:2772,
DOI:https://doi.org/10.1038/s41598-020-59772-z
 31. Majid K, Majid B, Fateh R. Detection of TEM, SHV and CTX-M antibiotic resistance genes in *Escherichia coli* Isolates from Infected wounds. *Medical Laboratory Journal.* 2017;11(2):30-35.
DOI:http://dx.doi.org/10.18869/acadpub.mlj.11.2.30
 32. Pandit R, Awal B, Shrestha SS, Joshi G, Rijal BP, Parajuli NP. Extended-Spectrum β -lactamase(ESBL) genotypes among multidrug-resistant uropathogenic *Escherichia coli* clinical isolates from a teaching hospital of Nepal. *Interdisciplinary Perspectives on Infectious Diseases.* 2020;8.
DOI:http://doi.org/10.1155/2020/6525826
 33. Michael NS, Saadi AT. Detection of bla CTX-M,blaTEM01 and blaSHV genes in multidrug resistant uropathogenic *E. coli* isolated from patients with recurrent urinary tract infections. *International Journal of Medical Research & Health Sciences.* 2018;7(9):81-89.
 34. Sahoo S, Otta S, Swain B, Kar SK. Detection and genetic characterization of extended-spectrum beta-lactamases producers in a tertiary care hospital. *J Lab Physicians.* 2019 Jul-Sep;11(3):253-258.
DOI:https://doi.org/10.4103/jlp.jlp_31_19
 35. Jena J, Sahoo RK, Debata NK, Subudhi E. Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum beta-lactamases-producing *Escherichia coli* strains isolated from urinary tract infections in adults. *Biotech.* 2017;7(4):244.
DOI:https://doi.org/10.1007/s13205-017-0879-2
 36. Kpoda, D.S., Ajayi, A., Somda, M. et al. Distribution of resistance genes encoding

- ESBLs in Enterobacteriaceae isolated from biological samples in health centers in Ouagadougou, Burkina Faso. BMC Res Notes. 2018;11:471.
DOI:<https://doi.org/10.1186/s13104-018-3581-5>
37. Sadeghi M, Sedigh Ebrahim-Saraie H, Mojtahedi A. Prevalence of ESBL and AmpC genes in *E. coli* isolates from urinary tract infections in the north of Iran. New Microbes New Infect. 2021;20:45:100947.
DOI:<https://doi.org/10.1016%2Fj.nmni.2021.100947>
38. Lohani B, Thapa M, Sharma L, Adhikari H, Sah AK, Khanal AB, Basnet RB, Aryal M. Predominance of CTX-M type extended spectrum β lactamase (ESBL) producers among clinical isolates of enterobacteriaceae in a Tertiary Care Hospital, Kathmandu, Nepal. The Open Microbiology Journal. 2019;13:28-33.
DOI:<http://dx.doi.org/10.2174/1874285801913010028>
39. Abimbola Olumide Adekanmbi, Miracle Opeyemi Akinpelu, Adedolapo Victoria Olaposi, Abolade A. Oyelade. Extended spectrum beta-lactamase encoding gene-fingerprints in multidrug resistant *Escherichia coli* isolated from wastewater and sludge of a hospital treatment plant in Nigeria. International Journal of Environmental Studies. 2021;78:1:140-150.
DOI:<https://doi.org/10.1080/00207233.2020.1778271>
40. Parajuli NP, Maharjan P, Joshi G, Khanal PR. Emerging perils of extended spectrum β -lactamase producing enterobacteriaceae clinical isolates in a Teaching Hospital of Nepal. Biomed Research International. 2016;7.
DOI:<https://doi.org/10.1155/2016/1782835>

© 2022 Chaudhary et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/93917>